Acute myeloid leukemia: current progress and future directions von Kantarjian, Hagop, Kadia, Tapan, DiNardo, Courtney, Daver, Naval, Borthakur, Gautam, Jabbour, Elias, Garcia-Manero, Guillermo, Konopleva, Marina, Ravandi, Farhad

Volltext

De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017 von Sasaki, Koji, Ravandi, Farhad, Kadia, Tapan M., DiNardo, Courtney D., Short, Nicholas J., Borthakur, Gautam, Jabbour, Elias, Kantarjian, Hagop M.

Volltext

Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges von Short, Nicholas J, Konopleva, Marina, Kadia, Tapan M, Borthakur, Gautam, Ravandi, Farhad, DiNardo, Courtney D, Daver, Naval

Volltext

Maintenance therapy in acute myeloid leukemia: advances and controversies von Senapati, Jayastu, Kadia, Tapan M, Ravandi, Farhad

Volltext

Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach von Kantarjian, Hagop M., Kadia, Tapan M., DiNardo, Courtney D., Welch, Mary Alma, Ravandi, Farhad

Volltext

Maintenance therapy in AML: The past, the present and the future von Molica, Matteo, Breccia, Massimo, Foa, Roberto, Jabbour, Elias, Kadia, Tapan M.

Volltext

TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes von Kadia, Tapan M., Jain, Preetesh, Ravandi, Farhad, Garcia‐Manero, Guillermo, Andreef, Michael, Takahashi, Koichi, Borthakur, Gautam, Jabbour, Elias, Konopleva, Marina, Daver, Naval G., Dinardo, Courtney, Pierce, Sherry, Kanagal‐Shamanna, Rashmi, Patel, Keyur, Estrov, Zeev, Cortes, Jorge, Kantarjian, Hagop M.

Volltext

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions von Daver, Naval G, Maiti, Abhishek, Kadia, Tapan M, Vyas, Paresh, Majeti, Ravindra, Wei, Andrew H, Garcia-Manero, Guillermo, Craddock, Charles, Sallman, David A, Kantarjian, Hagop M

Volltext

Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia von Tambaro, Francesco Paolo, Singh, Harjeet, Jones, Emily, Rytting, Michael, Mahadeo, Kris M., Thompson, Philip, Daver, Naval, DiNardo, Courtney, Kadia, Tapan, Garcia-Manero, Guillermo, Chan, Tim, Shah, Rutul R., Wierda, William G.

Volltext

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax von Kim, Kunhwa, Maiti, Abhishek, Loghavi, Sanam, Pourebrahim, Rasoul, Kadia, Tapan M., Rausch, Caitlin R., Furudate, Ken, Daver, Naval G., Alvarado, Yesid, Ohanian, Maro, Sasaki, Koji, Short, Nicholas J., Takahashi, Koichi, Yilmaz, Musa, Tang, Guilin, Ravandi, Farhad, Kantarjian, Hagop M., DiNardo, Courtney D., Konopleva, Marina Y.

Volltext

Maintenance Therapy in AML von Reville, Patrick K, Kadia, Tapan M

Volltext

Ibrutinib and Venetoclax for First-Line Treatment of CLL von Jain, Nitin, Keating, Michael, Thompson, Philip, Ferrajoli, Alessandra, Burger, Jan, Borthakur, Gautam, Takahashi, Koichi, Estrov, Zeev, Fowler, Nathan, Kadia, Tapan, Konopleva, Marina, Alvarado, Yesid, Yilmaz, Musa, DiNardo, Courtney, Bose, Prithviraj, Ohanian, Maro, Pemmaraju, Naveen, Jabbour, Elias, Sasaki, Koji, Kanagal-Shamanna, Rashmi, Patel, Keyur, Jorgensen, Jeffrey, Garg, Naveen, Wang, Xuemei, Sondermann, Katrina, Cruz, Nichole, Wei, Chongjuan, Ayala, Ana, Plunkett, William, Kantarjian, Hagop, Gandhi, Varsha, Wierda, William

Volltext

Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3‐internal tandem duplication genotypes von Boddu, Prajwal C., Kadia, Tapan M., Garcia‐Manero, Guillermo, Cortes, Jorge, Alfayez, Mansour, Borthakur, Gautam, Konopleva, Marina, Jabbour, Elias J., Daver, Naval G., DiNardo, Courtney D., Naqvi, Kiran, Yilmaz, Musa, Short, Nicholas J., Pierce, Sherry, Kantarjian, Hagop M., Ravandi, Farhad

Volltext

FLT3 inhibitors in acute myeloid leukemia: increasing options von Kadia, Tapan M

Volltext

Changing paradigms in the treatment of acute myeloid leukemia in older patients von Bazinet, Alexandre, Kadia, Tapan M

Volltext

Final results of a phase 2, open‐label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic s... von Assi, Rita, Kantarjian, Hagop M., Kadia, Tapan M., Pemmaraju, Naveen, Jabbour, Elias, Jain, Nitin, Daver, Naval, Estrov, Zeev, Uehara, Taisuke, Owa, Takashi, Cortes, Jorge E., Borthakur, Gautam

Volltext

RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1 von Mill, Christopher P., Fiskus, Warren, DiNardo, Courtney D., Qian, Yimin, Raina, Kanak, Rajapakshe, Kimal, Perera, Dimuthu, Coarfa, Cristian, Kadia, Tapan M., Khoury, Joseph D., Saenz, Dyana T., Saenz, David N., Illendula, Anuradha, Takahashi, Koichi, Kornblau, Steven M., Green, Michael R., Futreal, Andrew P., Bushweller, John H., Crews, Craig M., Bhalla, Kapil N.

Volltext

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study von Daver, Naval, Garcia-Manero, Guillermo, Basu, Sreyashi, Boddu, Prajwal C, Alfayez, Mansour, Cortes, Jorge E, Konopleva, Marina, Ravandi-Kashani, Farhad, Jabbour, Elias, Kadia, Tapan, Nogueras-Gonzalez, Graciela M, Ning, Jing, Pemmaraju, Naveen, DiNardo, Courtney D, Andreeff, Michael, Pierce, Sherry A, Gordon, Tauna, Kornblau, Steven M, Flores, Wilmer, Alhamal, Zainab, Bueso-Ramos, Carlos, Jorgensen, Jeffrey L, Patel, Keyur P, Blando, Jorge, Allison, James P, Sharma, Padmanee, Kantarjian, Hagop

Volltext

Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management von Rausch, Caitlin R., Jabbour, Elias J., Kantarjian, Hagop M., Kadia, Tapan M.

Volltext

Release the hounds: virotherapy with immunotherapy von Kadia, Tapan M.

Volltext